I can't waste anymore time on SH anymore, there simply isn't any fruitful discussion about the company and its posibilities.

Too many bashers and haters.

Those that attended to AGM seem satified that the trial is running well. I would agree based upon the first three patients. It sounds like they will begin the next six soon following the screening process.

I feel the second half of the year will see the stock apppreciate due to the expexctation of results. First three results could even suprise and look promising even at the lower dose.

time will tell

Macer